<DOC>
	<DOC>NCT00111306</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety &amp; efficacy of Epratuzumab with standard treatments for patients with SLE.</brief_summary>
	<brief_title>Study of Epratuzumab in Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Has SLE by ACR revised criteria (meets &lt;4 criteria); Has SLE with at least one elevated lupus antibody; Has new onset of severe lupus disease flare in at least one body or organ system, excluding renal or neurologic Active severe CNS or Renal disease defined by BILAG as Level A Allergy to murine or human antibodies Antiphospholid antibodies AND a history of thrombocytopenic events</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Antibody</keyword>
	<keyword>B-cell immunotherapy</keyword>
</DOC>